首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

【2h】

Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

机译：含有亚氨植物 - 西兰拉汀蛋白 - 重新粘液与蛋白酶蛋白-Cilastatin-Cilastatin的治疗群体之间的分析群体与蛋白质 - 非肌氨酰胺 - 非肌肌氨酰胺 - 非肌氨基脲 - 非肌氨基脲 - 非肌氨基脲 - 非肌氨基脲 - 非肌蛋白酶感染的治疗结果比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Antimicrobial Agents and Chemotherapy
作者
Keith S. Kaye; Helen W. Boucher; Michelle L. Brown; Angela Aggrey; Ireen Khan; Hee-Koung Joeng; Robert W. Tipping; Jiejun Du; Katherine Young; Joan R. Butterton; Amanda Paschke;
展开▼
作者单位

展开▼
年(卷),期 2020(64),5
年度 2020
页码 e02203-19
总页数 10
原文格式 PDF
正文语种
中图分类药学;微生物学;
关键词

机译：Carbapenem抗性;补充分析群;局部微生物学数据;β-内酰胺酶抑制剂;

相似文献

外文文献
中文文献
专利

1. Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study [J] . Michelle L Brown, Johann Motsch, Keith S Kaye, Open Forum Infectious Diseases . 2020,第3期

机译：在随机化，第3期恢复-IMI 1研究中，IMIPENEM / Creebactam和Colistin Plus Imipenem对癌症患者的肾脏安全性评估
2. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial [J] . Portsmouth Simon, van Veenhuyzen David, Echols Roger, The Lancet infectious diseases . 2018,第12期

机译：Cefideroon与Imipenem-Cilastatis治疗革兰阴性尿膜异常引起的复杂尿路感染：2阶段，随机，双盲，非劣等试验
3. CANVAS 1 and 2: Analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections [J] . FriedlandH.D., ONealT., BiekD., Antimicrobial agents and chemotherapy. . 2012,第5期

机译：CANVAS 1和2：头孢洛林fosamil与万古霉素加氨曲南的两项3期试验在第3天的临床反应分析，用于治疗急性细菌性皮肤和皮肤结构感染
4. Clinical randomized controlled trials of azithromycin injection in the treatment of bacterial infection [C] . Yin Jie, Shi Yi, Xia Xirong 7th China-Japan International Congress of Microbiology Shanghai Symposium-2000 4-6 August 2000 Shanghai . 2000

机译：阿奇霉素注射液治疗细菌感染的临床随机对照试验
5. Hypotensive resuscitation versus standard fluid resuscitation for the management of trauma patients in hemorrhagic shock: The safety phase of a randomized controlled trial. [D] . Morrison, C. Anne. 2009

机译：低血压复苏与标准液体复苏在失血性休克中对创伤患者的处理：一项随机对照试验的安全性阶段。
6. 1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections [O] . Keith Kaye, Thomas File, Helen W Boucher, -1

机译：1339.患有RESTORE-IMI的补充微生物改良意向治疗（SmMITT）人群的结果亚胺培南/西拉他汀/雷巴坦（IMI / REL）与亚胺培南/西拉他汀加colistin（IMI + CST）的试验亚胺培南不敏感（NS）细菌感染
7. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections [O] . Stephanie Noviello, G. Ralph Corey, Thomas L. Holland, 2020

机译：第3阶段恢复试验中伤口感染患者的汇总分析：随机，双盲研究，评价ICLAPRIM与万古霉素治疗急性细菌皮肤和皮肤结构感染的安全性和功效

Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

著录项

相似文献

相关主题

期刊订阅